Top Movers

S&P 500 Nears Record High, Market Buoyed by Rate Cut Hopes

Intraday

By Bill Bullington

5/15, 13:38 EDT
article-main-img

Key Takeaway

  • S&P 500, Nasdaq 100, and Dow Jones eye record closes amid optimism for Federal Reserve rate cuts, with the S&P 500 up by 1%.
  • BioCryst Pharmaceuticals surges 19% on insider buys; GoodRx climbs 11% after Kroger deal; Petco jumps 19% with new executive chairman.

Market Optimism Amidst Individual Volatility

The S&P 500 Index is experiencing a notable uptick, climbing 1% by midday in New York, hinting at a potential record close. This surge in optimism is largely fueled by the latest U.S. consumer price report, which has sparked hopes for upcoming Federal Reserve interest rate cuts. Similarly, the Nasdaq 100 and the Dow Jones Industrial Average are enjoying gains of 1.3% and 0.7%, respectively, with the MSCI World Index also up by 0.4%, all eyeing record closes.

Highs and Lows Across the Board

Today's trading session showcases a broad spectrum of performance among U.S. equities. Arcos Dorados finds itself on the downside, with shares dropping 5.4% due to disappointing first-quarter earnings, primarily affected by its South Latin American Division. Conversely, B&G Foods sees a significant uptick, with shares jumping 7.7% following insider purchases totaling $1.22 million.

Insider Confidence and Strategic Moves

BioCryst Pharmaceuticals stands out with a 19% increase in its shares after disclosures of over $800,000 in stock purchases by insiders, including the CEO. GoodRx also makes headlines with an 11% climb after announcing a new direct contracting agreement with Kroger, promising improved prescription pricing. Meanwhile, Petco Health & Wellness enjoys a 19% surge, buoyed by the market's positive reaction to Glenn Murphy's appointment as executive chairman.

Mixed Results in Tech and Retail

In the tech sector, Infinera's shares dip by 3.5% following a preliminary revenue report that fell short of expectations, marking a weak performance despite surpassing fourth-quarter consensus estimates. On the retail front, J Jill Inc reports a 9.1% increase after announcing additional voluntary debt repayments and preliminary net sales that met expectations.

Emerging Therapeutics and Entertainment

Kyverna Therapeutics and Taysha Gene Therapies both report positive developments, with shares up 6.7% and 17%, respectively. Kyverna advances in its clinical trial for autoimmune diseases, while Taysha updates on its Rett syndrome treatment. In the entertainment sector, TKO Group sees a 2% rise after an upgrade from Cowen, citing an attractive entry point for investors.